✦ LIBER ✦

Therapies for Exacerbation of Myasthenia Gravis: The Mechanism of Action of Intravenous High-Dose Immunoglobulin G

✍ Scribed by BRUNO FERRERO; LUCA DURELLI; ROBERTO CAVALLO; ANNA DUTTO; GIUSEPPE AIMO; FERNANDO PECCHIO; BRUNO BERGAMASCO

Book ID: 119868571
Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 199 KB
Volume: 681
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.1993.tb22941.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose intravenous immunoglobulin G t

High-dose intravenous immunoglobulin G treatment of myasthenia gravis

✍ B. Ferrero; L. Durelli 📂 Article 📅 2002 🏛 Springer Milan 🌐 English ⚖ 184 KB

Treatment of myasthenia gravis with high

Treatment of myasthenia gravis with high-dose intravenous immunoglobulin

✍ V. Cosi; M. Lombardi; G. Piccolo; A. Erbetta 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB

Intravenous immunoglobulin for prophylax

Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis

✍ Sorgun, Mine Hayriye; Sener, Huseyin Ozden; Yucesan, Canan; Yucemen, Nezih 📂 Article 📅 2014 🏛 Springer Milan 🌐 English ⚖ 218 KB

On the mechanism of high dose intravenou

On the mechanism of high dose intravenous immunoglubulin (IVIG) action in myasthenia gravis (MG)

✍ E. Morel; R. Liblau; Ph. Gajdos 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 62 KB

High-dose intravenous immunoglobulin for

High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis

✍ Hirokatsu Takahashi; Naoki Kawaguchi; Yuko Nemoto; Takamichi Hattori 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

High dose intravenous immunoglobulin tre

High dose intravenous immunoglobulin treatment: Mechanisms of action

✍ Peter Boros; Gabriel Gondolesi; Jonathan S. Bromberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

Intravenous immunoglobulin (IVIg) treatment was introduced as replacement therapy for patients with antibody deficiencies, but evidence suggests that a wide range of immune-mediated conditions could benefit from IVIg. The immunoglobulins are precipitated from human plasma by fractionation methods. I